(VIANEWS) – The Market ended the session with ULTIMOVACS (ULTI.OL) jumping 25.58% to kr140.40 on Wednesday while Oslo Børs Benchmark Index_GI rose 0.19% to kr1,312.26.
ULTIMOVACS’s last close was kr111.80, 21.6% under its 52-week high of kr142.60.
About ULTIMOVACS
Ultimovacs ASA, a biotech company, develops immunotherapies against cancers. Its lead product candidate is UV1, a peptide-based cancer vaccine that induces a specific T cell response against the universal cancer antigen telomerase. The company was incorporated in 2011 and is headquartered in Oslo, Norway.
Earnings Per Share
As for profitability, ULTIMOVACS has a trailing twelve months EPS of kr-5.66.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -40.11%.
Volatility
ULTIMOVACS’s last week, last month’s, and last quarter’s current intraday variation average was a negative 0.49%, a positive 2.14%, and a positive 2.56%.
ULTIMOVACS’s highest amplitude of average volatility was 5.66% (last week), 4.19% (last month), and 2.56% (last quarter).
More news about ULTIMOVACS (ULTI.OL).
